R S Chang

Asperlicin, a novel non-peptidal cholecystokinin antagonist from Aspergillus alliaceus. Fermentation, isolation and biological properties.

R. Chang, R. Monaghan, M A Goetz, 1985, The Journal of antibiotics.

Novel glutamic acid derived cholecystokinin receptor ligands.

R. Freidinger, W. L. Whitter, R. Chang, 1990, Journal of medicinal chemistry.

A potent nonpeptide cholecystokinin antagonist selective for peripheral tissues isolated from Aspergillus alliaceus.

J M Liesch, R. Chang, O. Hensens, 1985, Science.

Methods for drug discovery: development of potent, selective, orally effective cholecystokinin antagonists.

B. E. Evans, D. Veber, K. Rittle, 1988, Journal of Medicinal Chemistry.

Nonpeptide angiotensin II antagonists derived from 4H-1,2,4-triazoles and 3H-imidazo[1,2-b][1,2,4]triazoles.

R. Chang, V. J. Lotti, M. Maccoss, 1993, Journal of medicinal chemistry.

Potent, orally active imidazo[4,5-b]pyridine-based angiotensin II receptor antagonists.

R. Chang, V. J. Lotti, P. Chakravarty, 1991, Journal of medicinal chemistry.

Asperlicin, a novel non-peptidal cholecystokinin antagonist from Aspergillus alliaceus. Structure elucidation.

J M Liesch, R. Chang, J. Springer, 1985, The Journal of antibiotics.

In vivo pharmacology of L-364,718, a new potent nonpeptide peripheral cholecystokinin antagonist.

R J Gould, R. Chang, R. Gould, 1987, The Journal of pharmacology and experimental therapeutics.